Stay updated on Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.

Latest updates to the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA Locations section listing participating sites across the United States, Australia, Canada, and Poland was added, and location listings were revised (some entries removed).SummaryDifference2%

- Check21 days agoNo Change Detected
- Check43 days agoChange DetectedPubMed publications are now described as automatically populated from PubMed and may not all relate to the study. The revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.4%

- Check50 days agoChange DetectedThe government funding/operating status notice was removed; the study details and enrollment information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check64 days agoChange DetectedThe changes appear to be minor UI/layout adjustments with no substantive changes to core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check93 days agoChange DetectedUpdated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.SummaryDifference2%

- Check100 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.